As one of the country’s largest diagnostic service providers, Agilus is expanding access to advanced next-generation sequencing to support earlier detection, personalised treatment and better understanding of complex diseases.

Dr Ashutosh Raghuvanshi, MD and CEO of Fortis Healthcare, said the integration of NovaSeq X is an important milestone for India’s healthcare ecosystem. “High quality molecular insights are vital not only for oncology but also for diagnosing rare diseases, guiding targeted therapies, and advancing personalised and preventive care. Agilus’ investment brings cutting-edge science closer to patients and equips clinicians with actionable information to improve outcomes across a broad spectrum of conditions,” he said.

The NovaSeq X platform significantly enhances Agilus’ molecular testing capabilities, supporting whole genome sequencing, whole exome sequencing and multi-omic analysis with high speed and accuracy. Through Agilus’ nationwide network, these advanced capabilities are expected to reach clinicians and patients across both major cities and emerging markets.

Dr Anand K., Managing Director and CEO of Agilus Diagnostics, said the platform is central to the company’s long-term vision for precision healthcare. “The NovaSeq X strengthens our genomics and proteomics capabilities and enables faster, high-resolution insights that power personalised medicine. This brings us closer to delivering truly predictive and individualised care for patients across India,” he said.